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This study investigated long-term microenvironmental responses (oxygenation, perfusion, metabolic status, proliferation, vascular
endothelial growth factor (VEGF) expression and vascularisation) to chronic hypoxia in experimental tumours. Experiments were
performed using s.c.-implanted DS-sarcomas in rats. In order to induce more pronounced tumour hypoxia, one group of animals was
housed in a hypoxic atmosphere (8% O2) for the whole period of tumour growth (chronic hypoxia). A second group was acutely
exposed to inspiratory hypoxia for only 20min prior to the measurements (acute hypoxia), whereas animals housed under normal
atmospheric conditions served as controls. Acute hypoxia reduced the median oxygen partial pressure (pO2) dramatically (1 vs
10mmHg in controls), whereas in chronically hypoxic tumours the pO2 was significantly improved (median pO2¼4mmHg),
however not reaching the control level. These findings reflect the changes in tumour perfusion where acutely hypoxic tumours show
a dramatic reduction of perfused tumour vessels (maybe the result of a simultaneous reduction in arterial blood pressure). In animals
under chronic inspiratory hypoxia, the number of perfused vessels increased (compared to acute hypoxia), although the perfusion
pattern found in control tumours was not reached. In the chronically hypoxic animals, tumour cell proliferation and tumour growth
were significantly reduced, whereas no differences in VEGF expression and vascular density between these groups were observed.
These results suggest that long-term adaptation of tumours to chronic hypoxia in vivo, while not affecting vascularity, does influence
the functional status of the microvessels in favour of a more homogeneous perfusion.
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Oxygen deficiency (hypoxia) can be found in many human
malignancies (Vaupel et al, 1989; Ho ¨ckel and Vaupel, 2001) and
has been blamed for limiting the efficacy of several nonsurgical
tumour treatments such as sparsely ionising radiation (Gray et al,
1953; Bush et al, 1978; Horsman, 1993), O2-dependent chemother-
apeutic agents (Teicher et al, 1990; Thews et al, 2001) or
photodynamic therapy (Henderson and Fingar, 1987). However,
an increasing number of studies clearly demonstrate that tumour
hypoxia also has an impact on gene expression, with changes in
glycolytic enzymes, growth factors or angiogenic molecules (for a
recent review, see Ho ¨ckel and Vaupel, 2001). Many of these genes
are under the control of the hypoxia-inducible factor 1 (HIF-1),
which has been found to be accumulated in many tumours
(Semenza, 2000, 2002). Most of these processes of gene induction
are not tumour specific and also take place in the normal tissue
during hypoxia. However, some of them (e.g. hypoxia-induced
neovascularisation) may contribute to malignant progression and
metastasis (Dachs and Tozer, 2000). In particular, the formation of
new blood vessels in growing tumours, which is stimulated by
hypoxia-induced upregulation of the vascular endothelial growth
factor (VEGF) (Sutherland et al, 1996), seems to play an important
role in malignant progression. Folkman (1971, 1995) postulated
that tumour growth to macroscopic size only becomes possible as
a result of this neovascularisation induced by secretion of
angiogenic factors, as a result of which the improved tumour
blood flow ensures the supply of oxygen and nutrients necessary
for further cell proliferation (Harris, 2002). Thus, tissue hypoxia
seems to be important for a needs-related modification of the
oxygen and nutrient supply, the pH or the bioenergetic status,
which together form the so-called metabolic tumour microenvir-
onment. Hypoxia may therefore lead to an improvement in the
oxygenation status of the tumour and thus promote subsequent
tumour progression (Coleman et al, 2001). However, besides
hypoxia, other mechanisms (e.g. oncogene expression) also seem
to contribute to angiogenesis (Feldkamp et al, 1999; Zhang et al,
2001; Rak and Yu, 2004).
Vessels formed during hypoxia-induced angiogenesis show
several structural and functional abnormalities compared to those
in normal tissues. These abnormalities include blind endings of
vessels, irregular branching patterns, loss of vascular hierarchy,
absence of endothelial lining, increased vascular permeability and
high fraction of arterio-venous shunt perfusion (Konerding et al,
1989a,b, 1999; Vaupel et al, 1989, 2001), and may result in an
inadequate perfusion, which does not follow a regular pattern
(Vaupel et al, 1989). These abnormalities lead to increased
intervascular distances limiting the diffusive oxygen flux to the
tumour cells and thus result in an insufficient cellular O2 supply.
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sIn addition, tumour blood flow in these newly formed vessels has
been seen to undergo temporal fluctuations with intermittent flow
stops in individual vessels (Chaplin and Hill, 1995; Kimura et al,
1996).
From these findings it becomes clear that although hypoxia can
stimulate angiogenesis and by this may increase blood supply to
the tumour, it can at the same time cause limitations in the oxygen
supply due to the structural abnormalities of the newly formed
vessels. For this reason, the impact of long-term hypoxia on
changes in the vascular structure, perfusion or metabolic
microenvironment cannot be predicted. Due to hypoxia-induced
changes in the activities of glycolytic enzymes, the metabolic
behaviour of the tumour may change so that chronic hypoxia may
also induce fundamental changes in the microenvironment. These
aspects become even more important considering that the aim of
some therapeutic concepts is to increase tumour hypoxia (Wood
et al, 1994) in order to improve the efficacy of anticancer drugs,
which act preferentially on hypoxic cells (Coleman et al, 1984;
Brown, 1993; Greco et al, 2002; Wouters et al, 2002; Henk et al,
2003). At present, it is unclear what impact long-term hypoxia has
on the microenvironment of solid tumours. In particular, the
question arises whether chronic tumour hypoxia (over several
days) induces adaptive processes modulating the oxygen and
nutrient supply to the cells.
The aim of the present study was to assess changes in
oxygenation and metabolic and bioenergetic parameters as a
consequence of an increase in tumour hypoxia. The O2 status of
experimental tumours was therefore intentionally worsened by
inspiratory hypoxia over the whole period of tumour growth (6–14
days). Subsequently, oxygenation, metabolic and bioenergetic
parameters of the tumours were determined. In order to study
the underlying mechanisms by which the oxygen and nutrient
supply of the tissue was modified, vascularisation and perfusion
were evaluated.
MATERIALS AND METHODS
Animals and tumours
Male Sprague–Dawley rats (Charles River Deutschland, Sulzfeld,
Germany; body weight 190–240g) housed in our animal care
facility were used in this study. They received a standard diet and
acidified water ad libitum. Experimental tumours grew following
subcutaneous injection of DS-ascites tumour cells (0.4ml;
approximately 10
4cellsml
 1) into the dorsum of the hind foot, as
flat, spherical segments and replaced the subcutis and corium
completely. The volume was determined by measurement of the
three orthogonal diameters of the tumour and using an ellipsoid
approximation with the formula V¼d1d2d3p/6. Tumour volume
doubling time was calculated from growth curves during the
exponential growth phase (days 4–12 after inoculation). Micro-
environmental measurements were performed when tumours
reached a target volume of 0.5–3.0ml approximately 6–14 days
after inoculation. Animals were housed either under normoxic
ambient conditions (room air; 21% O2) or in a hypoxic atmosphere
containing 8% O2 (chronic hypoxia) continuously for the whole
period of tumour growth and during measurements (e.g.
oxygenation measurements). For experiments analysing the impact
of acute hypoxia, animals were housed under normoxic conditions
during tumour growth but breathed the hypoxic gas mixture (8%
O2) for 20min prior to and during the measurements. Studies had
previously been approved by the regional ethics committee and
were conducted according to UKCCCR guidelines (Workman et al,
1998) and the German Law for Animal Protection.
Tumour oxygen tensions
The distribution of tumour oxygen tensions (oxygen partial
pressure, pO2) was measured polarographically using steel-shafted
microelectrodes (outer diameter: 300mm) and the pO2 histography
system (Eppendorf, Hamburg, Germany; for more details of this
method, see Vaupel et al, 1991). A small midline incision was made
in the skin covering the lower abdomen and the Ag/AgCl reference
electrode was placed between the skin and the underlying
musculature. For tumour pO2 measurement, a small incision was
made in the skin overlying the tumour using a 24-gauge needle and
the electrode advanced to a depth of approximately 1mm. The
electrode was then automatically moved through the tissue in
preset steps with an effective step length of 0.7mm. Approximately
100 pO2 values were obtained from each tumour in up to eight
parallel electrode tracks. The oxygenation status of each tumour
was described by the mean and median pO2 as well as by the
fraction of pO2 values p2.5 and p5mmHg. Oxygenation studies
of individual tumours were generally carried out in less than
20min. Additionally, arterial blood gas analysis was performed
immediately before and after tumour tissue pO2 measurements
using a pH/blood gas analyser (type ABL 5, Radiometer,
Copenhagen, Denmark) to ensure that values for the arterial
blood gases were within the physiological range during the
measurement period. Mean arterial blood pressure (MABP) was
continuously monitored through connection of an arterial catheter
placed in the left carotid artery to a Statham pressure transducer
(type P 23 ID, Gould, Oxnard, CA, USA).
Metabolite concentrations
In order to analyse metabolic parameters, the tumour-bearing hind
limbs of the anaesthetised animals were rapidly frozen in liquid
nitrogen. Tumours were subsequently removed, ground to a fine
powder and freeze-dried. Thereafter, glucose and lactate concen-
trations were assayed enzymatically using standard test kits
(#1442457 and #256773; Boehringer-Mannheim, Mannheim, Ger-
many), and ATP, ADP and AMP were measured by HPLC (for
details of the methods, see Vaupel et al, 1994; Kelleher et al, 1995).
Vascular endothelial growth factor concentration
Vascular endothelial growth factor was determined by an ELISA
kit detecting rat VEGF (kit DY564, R&D Systems, Minneapolis,
MN, USA) according to the manufacturer’s instructions. In brief,
tumours were excised and cut into small pieces. Approximately
0.5g of tissue was suspended in 1.5ml RIPA buffer (phosphate-
buffered saline, NP-40, Na
þ-deoxycholateþproteinase inhibitor
cocktail), sonicated five times on ice and centrifuged. The protein
content of the supernatant was determined using Bradford reagent
(Sigma, Deisenhofen, Germany). For each measurement, approxi-
mately 50mg of protein was analysed. For this, 96-well microplates
were coated with a mouse anti-rat VEGF antibody. The super-
natant of the tissue preparation was diluted in PBSþ1% BSA
(1:10 vv
 1) and incubated in the wells for 2h at room
temperature. After washing, the detection antibody (goat anti-rat
VEGF) was added and incubated for a further 2h at room
temperature. The optical density was determined on a microplate
reader at a wavelength of 450nm. The VEGF concentration
determined for each well was normalised to the protein content
in the sample. In contrast to all other experiments, in the VEGF
study, the animals in the group ‘acute hypoxia’ were exposed to the
hypoxic atmosphere (8% O2) for 18h (not just for 20min) prior to
tumour excision in order to leave sufficient time for the in vivo
upregulation of VEGF expression to take place.
Vascular density
Endothelial cells were stained with a CD31 antibody. Cryosections
with a thickness of 7mm were fixed for 15min in acetone (41C).
Sections were rinsed in PBS (pH 7.4) and thereafter with 3% H2O2.
Sections were washed in PBS between all the following steps. The
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sspecimens were incubated in normal horse serum (Vector
Laboratories, Burlingame, CA, USA) for 20min and incubated
overnight in CD31 antibody (1:100, mouse anti-rat antibody
MCA1334G, Serotec, Oxford, UK) at room temperature in
humidified chambers. Biotinylated anti-mouse IgG (dilution
1:200, BA-2000, Vector Laboratories) was applied as a secondary
antibody for 30min, followed by ABC complex (peroxidase
standard kit, PK 4000, Vector Laboratories) for 30min. Immune
complexes were made visible by incubation with AEC chromogene
(peroxidase substrate kit, AEC SK-4200, Vector Laboratories) for
15min. The specimens were then counterstained with haematoxy-
lin (1:2) for 2min and rinsed in tap water. Finally, using aquatex
mounting medium (Merck, Darmstadt, Germany), specimens were
mounted with a coverslip.
All morphometric analyses were performed single-blinded by
the same observer using a computerised digital image analysis
system (Diskus 4.30, Hilgers, Ko ¨nigswinter, Germany) connected
with a Zeiss Axiophot microscope (Zeiss, Jena, Germany). In each
tumour, the areas with the highest microvessel density (hot spots)
were identified. Quantification of the microvessels was performed
in five hot spots in the tumour periphery and five hot spots in the
tumour centre. The vessel counts were averaged separately for the
tumour centre and periphery. Analysis of the fraction of viable
tumour tissue was performed in the haematoxylin and eosin-
stained slices by marking necrotic areas and calculating the
fraction of necrosis in the image.
Perfusion-related parameters
In order to assess parameters related to the perfusion distribution
within a tumour, the fluorescent dye Hoechst 33342 (Sigma,
Deisenhofen, Germany) was injected i.v. at a dose of 25mgkg
 1
body weight. For this, the dye was dissolved at a concentration of
10mgml
 1 in isotonic saline and approximately 0.5ml of this
stock solution was rapidly injected into a tail vein. At 60s after
injection, animals were killed by an overdose of anaesthetic and
the tumours were rapidly frozen in liquid nitrogen. Following
subsequent tumour removal, cryosections were prepared. Using
fluorescence microscopy (filter set #02, Zeiss, Jena, Germany,
excitation wavelength: 365nm, emission filter: low-pass 420nm) at
low resolution (range of vision 3 2.5mm), images of perfused
vessels were taken from two to three different regions of each
cryosection. Approximately three to four sections from each
tumour were analysed resulting in 9–10 images per tumour. In
these images, each vessel was marked and the mean density of
perfused vessels, the mean distance between neighbouring vessels
and the area of vascular domains were calculated using image
analysis software (Optimas Ver. 6.2, Media Cybernetics, Silver
Spring, MD, USA).
DNA content and proliferation analysis
For analysis of DNA content and the fraction of actively DNA-
synthesising cells, tumours were labelled with bromodeoxyuridine
(BrdU). For this, BrdU (Boehringer-Mannheim, Mannheim,
Germany) was dissolved in PBS at a concentration of 10mgml
 1
and injected i.p. (150mgkg
 1 body weight). After 120min,
tumours were excised and dissipated into a single cell suspension.
Incorporated BrdU was detected using monoclonal antibodies and
DNA content was determined by propidium iodide staining (for
details of the methods, see Thews et al, 1996).
Blood cell parameters
Blood cell parameters were assessed using a multiparameter,
automated haematology analyser (Ac-T8; Beckman-Coulter, Kre-
feld, Germany), whereby erythrocyte, white blood cell and platelet
counts together with the mean red blood cell (RBC) volume (MCV)
were measured by impedance and the haemoglobin concentration
was measured by a photometric method. In addition, the analyser
uses the measured values to calculate several other parameters (e.g.
haematocrit, mean corpuscular haemoglobin content (MCH)). All
measurements were performed using a sample of venous blood
(20ml) taken from a tail vein.
Statistical analysis
Results are expressed as means7s.e.m. unless stated otherwise.
Differences between groups were assessed by the two-tailed
Wilcoxon test for unpaired samples. The significance level was
set at a¼5% for all comparisons.
RESULTS
Exposing rats to an atmosphere containing a reduced oxygen
fraction (8%) over a prolonged period of time (6–14 days) affects
several systemic parameters. As might be expected, inspiratory
hypoxia markedly stimulated erythropoiesis, as indicated by a
significantly higher haemoglobin concentration and haematocrit
as well as an increased number of RBCs (Table 1). However, mean
erythrocyte volume (MCV) and cellular haemoglobin content
(MHC) remained in the normal range. In parallel, the spleen wet
weight of the animals was significantly reduced under hypoxic
conditions (0.8270.23g) compared to control animals
(1.0670.24g, P¼0.032). Hypoxia led to a significant reduction
in arterial pO2 followed by a stimulation of ventilation as indicated
by a lower arterial pCO2 and a higher pH (Table 2). Arterial pO2 in
chronically hypoxic animals was slightly higher compared to acute
hypoxia (3871 vs 3372mmHg), possibly indicating an adaptation
of ventilation to a chronically reduced inspiratory O2 fraction.
Housing animals under hypoxic environmental conditions also
had an impact on the growth behaviour of experimental tumours.
Under control conditions (breathing room air), the DS-sarcoma
used in the study had a volume doubling time of 2.4 days (during
the exponential growing phase), whereas tumours growing under
inspiratory hypoxia had a significantly longer volume doubling
time (3.0 days; Figure 1). Since the dependency of oxygenation,
bioenergetic status, fraction of viable tissue and perfusion on
tumour volume is well documented for many experimental tumour
models, all comparisons of these parameters in this study were
performed on tumours of comparable size. For this reason,
parameters were measured on different days after tumour
implantation when tumours reached a mean volume of approxi-
mately 1.5ml.
Although the cell cycle distribution was not markedly different
between the two groups, the fraction of actively DNA-synthesising
cells as measured by BrdU incorporation was significantly lower in
the group exposed to inspiratory hypoxia (Figure 2). Since the
fraction of cells in the S phase of the cell cycle was not different,
Table 1 RBC-related parameters in control animals and animals housed
under chronically hypoxic conditions (inspiratory O2 fraction¼8%) for the
whole period of tumour growth (6–14 days)
Control
Chronic
hypoxia P-value
n 76
cHb (gl
 1) 13774 16773 0.003
Haematocrit (%) 42715 1 71 0.003
RBC count (10
6ml
 1) 7.070.2 8.470.1 0.005
Mean corpuscular volume
(MCV) (fl)
59716 1 71 0.284
Mean corpuscular haemoglobin
(MCH) (pg)
20712 0 71 0.316
n¼number of tumours investigated; cHb¼haemoglobin concentration.
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sthe fraction of cells not incorporating BrdU during the S phase was
slightly higher in chronically hypoxic cells than under control
conditions. These data indicate a prolongation of the cell cycle S
phase during chronic hypoxia rather than an arrest of cells during
proliferation.
Inspiratory hypoxia strongly affects the oxygenation status of
the tumour. An acute reduction in the inspiratory O2 fraction to
8% reduces the median pO2 from 10mmHg (control) to 1mmHg
within 20min (Figure 3). In parallel, the fraction of hypoxic pO2
values p2.5mmHg significantly increased from 17 to 77%
(Figure 3). However, during chronic hypoxia (lasting the whole
period of tumour growth), the worsening of the O2 status was less
pronounced: the median pO2 was 4mmHg and the fraction of
hypoxic pO2 values p2.5mmHg was 44% (Figure 3).
These differences in tumour oxygenation also have an impact on
the metabolic and bioenergetic status. Although the glucose
concentration in the tumours was not markedly different between
the three groups (control: 1.3570.13mmolg
 1; acute hypoxia:
1.4370.10mmolg
 1; chronic hypoxia: 1.0770.10mmolg
 1), the
lactate level in the group acutely exposed to inspiratory hypoxia
was significantly higher compared to control animals and to
chronically hypoxic tumours (Figure 4A), presumably indicating
an increased level of glycolysis. In turn, the ATP concentration in
the acute hypoxia tumours was significantly lower compared to
those in control animals and under chronic hypoxia (Figure 4B).
Although the results of tumour oxygenation and metabolic
parameters indicate that the O2 supply and thus the energy yield
are reduced during inspiratory hypoxia, the tumour tissue was still
found to be non-necrotic. The fraction of viable tissue was 7073%
in control tumours and 7576% in tumours grown under
chronically hypoxic conditions. Even though apoptosis was not
measured directly in this study, the fraction of tumour cells with a
DNA content below that of G0 cells can be used as a measure of
apoptosis. This fraction was found to be low in chronically hypoxic
as well as in control tumours (971 and 571%, respectively;
P¼0.002).
In addition, no marked differences were seen in the vascularity
of tumours in both groups (Figure 5A and B). In order to analyse
the impact of inspiratory hypoxia (resulting in a pronounced O2
deficiency in the tumour) on the induction of vessel formation, the
vascular densities in areas of high vascular density (hot spots) in
the tumour centre and periphery were determined. However,
neither the size of the hot spots nor the mean or maximum
vascular density within the hot spots (Table 3) was markedly
different (and not statistically significant) between the groups
Table 2 Arterial pO2, pCO2 and pH in control animals, in animals during
acute reduction of the inspiratory O2 fraction for 20min (acute hypoxia)
and during chronic inspiratory hypoxia for 6–14 days (chronic hypoxia)
np O2 (mmHg) pCO2 (mmHg) pH
Control 19 78714 8 71 7.4170.03
Acute hypoxia 22 3372* 3271* 7.5070.01*
Chronic hypoxia 17 3871*
, ** 2972* 7.4970.01*
n¼number of tumours investigated. *Po0.001 vs control; **Po0.05 vs acute
hypoxia.
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Figure 2 Fraction of actively DNA-synthesising cells as measured by
BrdU incorporation during chronic inspiratory hypoxia (n¼8) and under
control conditions (n¼18).
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Figure 3 (A) Median tumour pO2 and (B) fraction of hypoxic pO2
values p2.5mmHg during chronic inspiratory hypoxia (chronic hypoxia,
n¼17), acute reduction of the inspiratory O2 fraction for 20min (acute
hypoxia, n¼18) and under normoxic control conditions (n¼21).
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sstudied. The results of the vascularity evaluation reflect the
findings of the VEGF concentration measurements. Even though
the DS-sarcoma cells are able to upregulate VEGF expression
under hypoxic conditions in vitro (data not shown), no marked
differences in the VEGF level in tumours of the different groups
were seen in the in vivo situation (Figure 6). Higher VEGF
concentrations as compared to controls were not found either in
tumours of animals kept under hypoxia only for 18h prior to
tumour excision (‘acute hypoxia’) or in animals housed for the
whole period of tumour growth in an oxygen-reduced atmosphere
(‘chronic hypoxia’).
Even though the number of vessels (as indicated by CD31
staining) was not different in chronically hypoxic tumours as
compared to controls (Figure 5A and B), the pattern of perfusion
distribution varied profoundly (Figure 5C–E). In acutely hypoxic
tumours, the density of perfused vessels was more than halved as
compared to control animals (Figures 5D and 7A). In parallel, the
mean distance between neighbouring perfused vessels was
dramatically increased (6557181mm) to values far greater than
the oxygen diffusion distance. In tumours under chronic
inspiratory hypoxia conditions, the mean number of perfused
vessels was also reduced to approximately the same extent as
during acute hypoxia (Figure 7A). However, the spatial distribu-
tion of perfusion in these tumours was much less heterogeneous
(Figure 5E). In chronically hypoxic tumours, the mean inter-
vascular distance between perfused vessels was markedly reduced
(3177114mm, although due to large interindividual variability it
was not statistically significant). These data indicate a trend to a
more uniform perfusion compared to acute hypoxia, although
values of control tumours were not reached (13473mm). This
trend also becomes obvious when the fraction of vessels that are
more than 350mm away from the next perfused vessel is calculated
(Figure 7B). One possible reason for the reduced perfusion seen
during inspiratory hypoxia despite a constant number of tumour
vessels may be a decrease in MABP during hypoxia. In control
animals, MABP was 13972mmHg, in acute hypoxia it was
reduced to 7772mmHg and in animals kept chronically under
hypoxia it was 8873mmHg (P¼0.0052 vs acute hypoxia).
DISCUSSION
In the present study, the impact of pronounced chronic hypoxia on
adaptive processes in tumours has been analysed. For this,
experimental tumours, which show O2 deficiency even under
control conditions (approximately 20% pO2 values below
2.5mmHg), were artificially made even more hypoxic by exposing
the animals to a hypoxic atmosphere containing 8% oxygen for the
period of tumour growth. However, this procedure induces severe
hypoxia systemically in the whole animal rather than just in the
tumour. Therefore, several other processes that are not directly
related to tumour hypoxia and that in turn may affect the tumour
microenvironment might be induced. For instance, the measured
blood gas parameters (Table 2) indicate that during acute as well as
during chronic inspiratory hypoxia, ventilation was stimulated and
a respiratory alkalosis was induced leading to a higher affinity of
O2 to haemoglobin (as indicated by a left shift of oxyhaemoglobin
dissociation curve). This mechanism may contribute to the
worsening of the O2 supply to the tumour and by this increase
tumour hypoxia. On the other hand, hypoxaemia induces
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Figure 4 (A) Mean lactate and (B) ATP concentrations in tumours
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Figure 5 Examples of vascular patterns (CD31 staining) in tumours
growing under either (A) normoxic conditions or (B) during chronic
inspiratory hypoxia, and of perfusion distribution (Hoechst 33342 staining)
under (C) normoxic control conditions, during (D) acute reduction of the
inspiratory O2 fraction for 20min or during (E) chronic inspiratory hypoxia.
All images are scaled to the same magnification.
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serythropoietin (EPO) formation in the kidney resulting in forced
erythropoiesis (as was the case in the present study; Table 1). Since
several tumour cell lines express an EPO receptor (Acs et al, 2001),
it has been discussed that erythropoietin may promote tumour
growth (Acs et al, 2003). However, for the tumour line used in the
present study (DS-sarcomas of the rat), it has been shown that EPO
per se has no promoting effect on proliferation (Thews et al, 1998).
On the other hand, secondary indirect effects of EPO on the
tumour microenvironment (e.g. by increasing the haemoglobin
level of the blood and by this improving the oxygen transport
capacity; Table 1) cannot be ruled out in the present study.
Therefore, the results obtained from the artificial situation of
systemic hypoxia can only be transferred with caution to the
situation found clinically in tumour patients.
The oxygen deficiency seen in many experimental and human
tumours results from a discrepancy between oxygen demand and
supply to the tissue. In particular, the convective oxygen transport
with the blood is insufficient since the tumour vasculature shows
chaotic vessel structure (Konerding et al, 1989a,b, 1999) resulting
in a loss of coordinated blood flow (Vaupel et al, 1989; Secomb
et al, 1995). In addition, temporary stasis of blood flow has been
described in many experimental and human tumours (Chaplin and
Hill, 1995). During systemic hypoxia, tumour blood flow becomes
even worse whereby pronounced differences in the perfusion
pattern of tumours were seen between acute and chronic hypoxia.
During short-term hypoxia, the number of perfused vessels was
dramatically decreased (Figures 5D and 7A), which may be the
result of a hypoxia-induced reduction in arterial blood pressure
(normoxia: 13972mmHg; acute hypoxia: 7772mmHg). Such a
decrease, which has also been described by others (Marshall and
Metcalfe, 1989; Sato et al, 1992; Trzebski et al, 1995) may have
several reasons. Inspiratory hypoxia has been shown to induce a
more pronounced formation of NO in the lung, which may then
lead to a systemic vasodilation resulting in a reduction of
perfusion pressure (Hubloue et al, 2003). It has also been
demonstrated that hypoxaemia can directly induce vasodilation
in various organs (e.g. brain, skeletal muscle) (Marshall and
Metcalfe, 1989; Harrison et al, 1990; Sato et al, 1992). However,
Harrison et al (1990) showed that in skeletal muscle hypoxaemia
presumably leads to an increase of perfusion of larger arteries
whereas capillary blood flow was only marginally improved
indicating a hypoxaemia-induced higher fraction of shunt perfu-
sion. Such a redistribution of blood flow may also play a part in the
present study in which pronounced systemic hypoxaemia is
Chronic
hypoxia
Acute
hypoxia
Control
0
20
40
60
80
100
120
140
V
E
G
F
 
(
p
g
 
m
g
 
p
r
o
t
e
i
n
−
1
)
 
Figure 6 Vascular endothelial growth factor concentration in tumours
during chronic inspiratory hypoxia (chronic hypoxia, n¼4), acute reduction
of the inspiratory O2 fraction for 18h prior to VEGF measurements (acute
hypoxia, n¼4) and under normoxic control conditions (n¼8).
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Figure 7 (A) Mean density of perfused vessels and (B) fraction of
vessels more than 350mm away from the next perfused vessel (as
determined by Hoechst 33342 injection) in cryosections of tumours during
chronic inspiratory hypoxia (chronic hypoxia, n¼12), acute reduction of
the inspiratory O2 fraction for 20min (acute hypoxia, n¼14) and under
normoxic control conditions (n¼10). In all control tumours, the distances
between neighbouring perfused vessels never exceeded 350mm.
Table 3 Area size of vascular ‘hot spots’, mean and maximum vascular density within the ‘hot spots’ in control tumours and in tumours grown under
chronically hypoxic conditions in vivo (inspiratory O2 fraction¼8%)
Tumour centre Tumour periphery
Control Chronic hypoxia Control Chronic hypoxia
n 61 0 61 0
Area of hot spots (mm
2) 0.2170.07 0.2270.04 0.1570.02 0.2170.04
Mean vascular density in the hot spots (vesselsmm
 2) 348749 258740 315755 322763
Maximum vascular density in the hot spots (vesselsmm
 2) 529762 385753 5077101 423780
Tumour areas both in the centre and periphery were analysed. n¼number of tumours investigated.
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blood flow to the disadvantage of the tumour resulting in a
reduction of perfusion disproportionate to the changes in
perfusion pressure (‘steal phenomenon’) (Hirst, 1989). Another
reason for this reduction in local perfusion could be a
vasoconstriction of vessels feeding the tumour. However, since
the tumours were implanted into the subcutis, this explanation
seems unlikely since a hypoxic vasoconstriction has only been
described in lung tissue.
Perfusion during acute inspiratory hypoxia was distributed very
heterogeneously as indicated by a pronounced increase in the
distance between neighbouring perfused vessels (Figures 5E and
7B) with a large intratumoral variability of this parameter. Tumour
regions with an almost normal perfusion distribution were found
closely adjacent to large areas of viable tumour tissue with almost
no perfusion. During chronic hypoxia, the mean number of
perfused vessels was not markedly changed as compared to acute
hypoxia. However, in chronic hypoxia, perfusion was distributed
much more homogeneously throughout the tissue as indicated by a
significant decrease in the distance between neighbouring perfused
microvessels (Figure 7B) with a smaller intraindividual variability.
One major consequence of the impaired tumour perfusion
occurring during systemic hypoxia is a worsening of convective
oxygen transport to the tissue. Due to the pronounced hetero-
geneity of tumour perfusion in acutely hypoxic tumours the
median tissue pO2 is markedly reduced, whereas during chronic
hypoxia the perfusion pattern becomes more homogeneous
leading to an improvement of tumour oxygenation (Figure 3).
However, in addition to the changes in the pattern of tumour
perfusion, other reasons for a long-term adaptation to chronic
hypoxia have to be considered. As described earlier (Tannock and
Steel, 1970; Amellem and Pettersen, 1991), induction of chronic
hypoxia reduced tumour cell proliferation as indicated by a slower
tumour growth and a lower fraction of actively DNA-synthesising
cells (Figures 1 and 2). This reduction in cell proliferation was not
seen in anaemic animals using the same tumour model (Thews
et al, 2001), presumably because anaemia resulted in an increase of
tumour hypoxia, which is less pronounced (Kelleher et al, 1996)
than that seen when animals were subjected to an atmosphere
containing only 8% oxygen. Even though the proliferation rate was
reduced in the present study, a cell cycle arrest in the G1 phase, as
has been described in cell culture experiments (Fujii et al, 2002),
was not found in the in vivo situation in the present study. The
fraction of cells in the G0/G1 phase in tumours under hypoxic
conditions was not significantly increased as compared to controls
breathing room air. For this reason, the differences in proliferation
and tumour growth rate found in vivo in the present study appear
to be attributable to a prolongation of the cell cycle rather than a
cell cycle arrest. Another explanation may be an alteration of the
G1/S checkpoint, which has been described in several tumours.
However, for the tumour model used in the present study
(experimental DS-sarcoma of the rat), the status of this checkpoint
is not known. For this reason, it might be possible that the lack of
hypoxia-induced cell cycle arrest results from a deficient G1/S
checkpoint. Since the oxygenation status of a tissue results from a
dynamic steady state between O2 delivery and consumption, the
reduced number of proliferating cells may also contribute to the
better oxygenation under these conditions (Thews et al, 1999).
However, a previous study showed that inhibition of DNA
synthesis does not necessarily result in a decrease in the O2
consumption rate of tumour cells in vivo (Thews et al, 1996).
Hirst et al (1987a, 1991) developed a model of adaptation of
tumours to long-term anaemia. They described that anaemia-
induced hypoxia acutely leads to a higher fraction of hypoxic cells
in the tumour. When hypoxia persisted over several days, the cord
of viable tumour cells around vessels was reduced, resulting in a
hypoxic fraction comparable to that found in nonhypoxic controls
(similar to the improvement of oxygenation in chronically
compared to acutely hypoxic tumours of the present study). This
model of adaptation is, however, not directly transferable to our
findings described here. If a reduced O2 diffusion radius is
proposed, the vascular density in these tumours should increase.
In the present hypoxia model used, no differences in the
morphological pattern of microvessels were found (in tumours
of comparable size and with similar fractions of necrotic tissue
regions). For this reason, other adaptive mechanisms have to take
place in addition to the reduction of the O2 diffusion distance.
In the experimental setting used, improvement of tumour
hypoxia during chronic inspiratory hypoxia may also be the result
of the increased haemoglobin concentration seen (Table 1), which
would lead to a higher oxygen transport capacity. Another
mechanism in this context has been proposed by Hirst and Wood
(1987a,b) and involves an adaptation of tumours to long-term
anaemia, again resulting in less pronounced tumour hypoxia. The
authors showed that an increase in the level of 2,3-diphos-
phoglycerate (2,3-DPG) in erythrocytes during inspiratory
hypoxia reduced the affinity of O2 to haemoglobin and by this
improved the oxygen supply to the tumour cells. Even though 2,3-
DPG levels were not determined in the present study, this
mechanism may also contribute to the long-term improvement
of the O2 status to chronic hypoxia. Finally, the arterial pO2 in
chronically hypoxic animals was slightly higher than during acute
hypoxia (Table 2), indicating an adaptation of ventilation to
chronic reduction of inspiratory O2 fraction. This higher arterial
pO2 may also (at least partially) contribute to the higher tumour
pO2 observed.
Another mechanism of long-term adaptation of tumour cells as
well as of host tissue cells (e.g. fibroblasts in the stroma) to
hypoxic conditions has to be ruled out in the present study. It has
been postulated that severe hypoxia may induce the formation of
new tumour blood vessels necessary for further tumour growth
(Folkman, 1995). In many human tumours, a close spatial
correlation of local oxygen deficiency (determined by assessment
of intrinsic or extrinsic hypoxia markers, eg, HIF-1a or EF5) and
the production of VEGF was found (Damert et al, 1997; Maxwell
et al, 1997; Blancher et al, 2000; Huss et al, 2001; Ziemer et al, 2001;
Buchler et al, 2003). Pilch et al (2001) showed in an in vitro
experiment that tumour cells – and even more so tumour stroma-
derived fibroblasts – increase their VEGF secretion rate when they
are kept under hypoxia (pO2 o1.5mmHg for 24h). Under these
conditions, tumour cells were able to increase the VEGF
production by up to 10-fold compared to the basal secretion
found under normoxia (pO2¼150mmHg). It should be noted,
however, that these results varied between the different cell lines
used. Fibroblasts were able to increase VEGF secretion by a factor
of four. DS-sarcoma cells used in the present study produce small
quantities of VEGF even under normoxic conditions (approxi-
mately 24pgh
 110
 6 cells). When these cells were kept under
hypoxia (pO2 o1.5mmHg for 24h), VEGF secretion increased by a
factor of six indicating that, in the tumour cell line used in the
present study, hypoxia is able to pronouncedly induce VEGF
formation in vitro. However, in vivo, the VEGF concentration in
the tumour was not markedly different in animals kept under
chronic hypoxia compared to normoxic conditions (Figure 6).
Since the HIF-1a level was not determined in the present study, it
remains unclear whether hypoxia in vivo leads to HIF-1
accumulation (either directly or indirectly by increasing the NO
concentration; Metzen et al, 2003) in the tumour model used.
However, notable is the finding that pronounced systemic and
tumour hypoxia was not able to increase VEGF concentrations
markedly. As a result of these unchanged VEGF levels, parameters
describing the vascular network (vascular density in tumour centre
and periphery) showed no significant differences (Table 3).
Several explanations for the lack of VEGF induction followed by
changes in the vascular structure in vivo as compared to cell
culture experiments have to be taken into account. Since the
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of pO2 values below 2.5mmHg (Thews et al, 1997), it may be that
VEGF production is maximally stimulated even when animals are
breathing room air, such that a further increase, due to a more
hypoxic environment, might not be possible. Another possible
reason for the lack of an increased VEGF induction may be that the
tissue hypoxia induced by a reduction of the inspiratory O2
fraction is not strong enough. Under in vitro conditions, VEGF is
induced following incubation at very low pO2 values (o1mmHg)
for several hours (Maity et al, 2001; Pilch et al, 2001). Even though
the median tumour pO2 was markedly reduced in the present study
by the reduction of the inspiratory O2 fraction to 8% (Figure 3), it
is conceivable that the tissue pO2 does not reach values low enough
to stimulate VEGF formation due to temporal fluctuations in the
oxygenation (Chaplin et al, 1987).
Inspiratory hypoxia led to marked changes in the metabolic and
bioenergetic status with a decreased glucose and ATP concentra-
tion and an increase in the lactate level (Figure 4). These findings
could be the result of pronounced tumour hypoxia leading to an
upregulation of enzymes of the glycolytic pathway leading to
increased lactate concentration, an acidic extracellular pH and a
reduced ATP yield seen in many tumours (Vaupel et al, 1994).
However, these findings could also be the result of the observed
reduction in tumour perfusion. In this case, the nutrient supply
(glucose) as well as the lactate elimination from the tissue would be
reduced. For this reason, the observed metabolic changes not only
reflect cellular adaptation to chronic hypoxia but also mirror
indirectly changes of tumour perfusion. Maybe, both mechanisms
together are responsible for the observed metabolic changes.
In conclusion, pronounced long-term hypoxia in an experi-
mental tumour induces adaptive processes resulting in an
improvement of the oxygenation status (as compared to acute
hypoxia). However, the increase in median pO2 does not result
from a hypoxia-induced angiogenesis (e.g. by induction of VEGF)
but from a functional adaptation of the perfusion pattern. Acute
hypoxia results in pronounced heterogeneity of the tumour blood
flow distribution, whereas chronic hypoxia leads to a more
homogeneous pattern with significantly smaller distances between
perfused vessels resulting in a better diffusive O2 supply to the
cells. In the tumour model used, functional changes in physiolo-
gical parameters appear to play a more important role in the
adaptation to chronic hypoxia than hypoxia-induced alterations in
VEGF expression and morphological changes of vasculature.
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